Anti-inflammatory and anti-viral actions of anionic pulmonary surfactant phospholipids

Numata, Mari; Voelker, Dennis R.

doi:10.1016/j.bbalip.2022.159139

Cited by 24 publications

(132 citation statements)

References 108 publications

(287 reference statements)

Supporting

Mentioning

123

Contrasting

Unclassified

Order By: Relevance

“…This builds on earlier studies showing that PG and PtdIns lipids block the binding of virus particles to host cell plasma membranes and can be used to suppress transmission (Voelker and Numata, 2019). Similarly, the specific interaction of the respiratory syncytial virus with PGbased liposomes inhibits viral attachment to host cells, suppresses infection in mouse models (Numata et al, 2010), and prevents damage to the lung (Numata and Voelker, 2022). The influenza virus binds tightly to PtdIns and PG in a concentration-dependent manner, and these lipids inhibit virus attachment to host cells, reducing viral burden in mouse and ferret models of infection, preventing lung damage and promoting survival (Numata et al, 2020).…”

Section: Discussionsupporting

confidence: 53%

“…The lipid interactions of viruses can also be directly exploited for therapeutic benefit. Both phosphatidylglycerol (PG) and PtdIns lipids exhibit anti-viral effects against SARS-CoV-2, suppressing viral burden and iScience Article preventing cytopathic effects in cellular models (Numata and Voelker, 2022). The use of lipids including PG for treating COVID-19 has been proposed (Bollag and Gonzales, 2020;Cattel et al, 2021;Ji et al, 2021;Veldhuizen et al, 2021), and clinical studies of administering phospholipid combinations for treatment of severe COVID-19 are showing improved patient outcomes (Bhatt et al, 2021;Busani et al, 2020;Dushianthan et al, 2020;Piva et al, 2021).…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Progressive membrane-binding mechanism of SARS-CoV-2 variant spike proteins

2022

View full text Add to dashboard Cite

Section: Discussionsupporting

confidence: 53%

Section: Discussionmentioning

confidence: 99%

Progressive membrane-binding mechanism of SARS-CoV-2 variant spike proteins

2022

View full text Add to dashboard Cite

“…Toll-like receptor 4 (TLR4) played an important role in the generation of an antiviral state after being infected with pathogenic viruses ( Boodhoo et al, 2022 ). A study of the human pluripotent stem cell–based model of SARS-CoV-2 infection demonstrated the involvement of TLR4 in the inflammatory activation of vascular endothelial cells ( Ma et al, 2022 ), and TLR4 was reported to contribute to anti-inflammatory effects and SARS-CoV-2 infection in vitro ( Numata and Voelker, 2022 ). Therefore, targeting the TLR4 inflammatory pathway could serve as a potential strategy in reducing inflammatory lung injury ( Bermudez et al, 2022 ).…”

Section: Discussionmentioning

confidence: 99%

In silico analysis and preclinical findings uncover potential targets of anti-cervical carcinoma and COVID-19 in laminarin, a promising nutraceutical

et al. 2022

View full text Add to dashboard Cite

Until today, the coronavirus disease 2019 (COVID-19) pandemic has caused 6,043,094 deaths worldwide, and most of the mortality cases have been related to patients with long-term diseases, especially cancer. Autophagy is a cellular process for material degradation. Recently, studies demonstrated the association of autophagy with cancer development and immune disorder, suggesting autophagy as a possible target for cancer and immune therapy. Laminarin is a polysaccharide commonly found in brown algae and has been reported to have pharmaceutic roles in treating human diseases, including cancers. In the present report, we applied network pharmacology with systematic bioinformatic analysis, including gene ontology (GO) enrichment, Kyoto Encyclopedia of Genes and Genomes (KEGG) enrichment analysis, reactome pathway analysis, and molecular docking to determine the pharmaceutic targets of laminarin against COVID-19 and cervical cancer via the autophagic process. Our results showed that the laminarin would target ten genes: CASP8, CFTR, DNMT1, HPSE, KCNH2, PIK3CA, PIK3R1, SERPINE1, TLR4, and VEGFA. The enrichment analysis suggested their involvement in cell death, immune responses, apoptosis, and viral infection. In addition, molecular docking further demonstrated the direct binding of laminarin to its target proteins, VEGFA, TLR4, CASP8, and PIK3R1. The present findings provide evidence that laminarin could be used as a combined therapy for treating patients with COVID-19 and cervical cancer.

show abstract

“…Identifying pulmonary surfactant changes in patients with COVID-19 and modifying surfactant preparations accordingly can mitigate potential risks. Some components of pulmonary surfactant possess anti-inflammatory or antiviral properties and help prevent alveolar collapse, such as PG and SP-D ( 14 , 16 , 74 ). Several studies have reported that these components exert therapeutic effects against viral respiratory infection ( 14 , 74 ).…”

Section: Future Prospectsmentioning

confidence: 99%

“…Some components of pulmonary surfactant possess anti-inflammatory or antiviral properties and help prevent alveolar collapse, such as PG and SP-D ( 14 , 16 , 74 ). Several studies have reported that these components exert therapeutic effects against viral respiratory infection ( 14 , 74 ). Clinical trial has been conducted to evaluate the safety and tolerated of AT-100 (rhSP-D) in patients with COVID-19 ( Table 1 ).…”

Section: Future Prospectsmentioning

confidence: 99%

Insights Gained Into the Treatment of COVID19 by Pulmonary Surfactant and Its Components

Wang

Liao

et al. 2022

Front. Immunol.

View full text Add to dashboard Cite

Pulmonary surfactant constitutes an important barrier that pathogens must cross to gain access to the rest of the organism via the respiratory surface. The presence of pulmonary surfactant prevents the dissemination of pathogens, modulates immune responses, and optimizes lung biophysical activity. Thus, the application of pulmonary surfactant for the treatment of respiratory diseases provides an effective strategy. Currently, several clinical trials are investigating the use of surfactant preparations to treat patients with coronavirus disease 2019 (COVID-19). Some factors have been considered in the application of pulmonary surfactant for the treatment COVID-19, such as mechanical ventilation strategy, timing of treatment, dose delivered, method of delivery, and preparation utilized. This review supplements this list with two additional factors: accurate measurement of surfactants in patients and proper selection of pulmonary surfactant components. This review provides a reference for ongoing exogenous surfactant trials involving patients with COVID-19 and provides insight for the development of surfactant preparations for the treatment of viral respiratory infections.

show abstract

Anti-inflammatory and anti-viral actions of anionic pulmonary surfactant phospholipids

Cited by 24 publications

References 108 publications

Progressive membrane-binding mechanism of SARS-CoV-2 variant spike proteins

Progressive membrane-binding mechanism of SARS-CoV-2 variant spike proteins

In silico analysis and preclinical findings uncover potential targets of anti-cervical carcinoma and COVID-19 in laminarin, a promising nutraceutical

Insights Gained Into the Treatment of COVID19 by Pulmonary Surfactant and Its Components

Contact Info

Product

Resources

About